Last reviewed · How we verify
PRN1008
At a glance
| Generic name | PRN1008 |
|---|---|
| Also known as | BTK inhibitor, Rilzabrutinib |
| Sponsor | Principia Biopharma, a Sanofi Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP) (PHASE2)
- Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) (PHASE3)
- Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan (PHASE3)
- Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants (PHASE2)
- Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants (PHASE1)
- Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA) (PHASE2)
- Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine (PHASE2)
- Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PRN1008 CI brief — competitive landscape report
- PRN1008 updates RSS · CI watch RSS
- Principia Biopharma, a Sanofi Company portfolio CI